| Literature DB >> 31551910 |
Parham Habibzadeh1,2, Soroor Inaloo3, Mohammad Silawi1, Hassan Dastsooz1,4, Mohammad Ali Farazi Fard1, Forough Sadeghipour1, Zahra Faghihi1, Mohaddeseh Rezaeian1, Majid Yavarian1, Johann Böhm5, Mohammad Ali Faghihi1,6.
Abstract
Mitochondrial complex III deficiency nuclear type 2 is an autosomal-recessive disorder caused by mutations in TTC19 gene. TTC19 is involved in the preservation of mitochondrial complex III, which is responsible for transfer of electrons from reduced coenzyme Q to cytochrome C and thus, contributes to the formation of electrochemical potential and subsequent ATP generation. Mutations in TTC19 have been found to be associated with a wide range of neurological and psychological manifestations. Herein, we report on a 15-year-old boy born from first-degree cousin parents, who initially presented with psychiatric symptoms. He subsequently developed progressive ataxia, spastic paraparesis with involvement of caudate bodies and lentiform nuclei with cerebellar atrophy. Eventually, the patient developed gastrointestinal involvement. Using whole-exome sequencing (WES), we identified a novel homozygous frameshift mutation in the TTC19 gene in the patient (NM_017775.3, c.581delG: p.Arg194Asnfs*16). Advanced genetic sequencing technologies developed in recent years have not only facilitated identification of novel disease genes, but also allowed revelations about novel phenotypes associated with mutations in the genes already linked with other clinical features. Our findings expanded the clinical features of TTC19 mutation to potentially include gastrointestinal involvement. Further functional studies are needed to elucidate the underlying pathophysiological mechanisms.Entities:
Keywords: TTC19; mitochondrial complex III deficiency; mitochondrial diseases; mitochondrial encephalomyopathies; neurodegenerative diseases
Year: 2019 PMID: 31551910 PMCID: PMC6737916 DOI: 10.3389/fneur.2019.00944
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Clinical, neuroimaging, and biochemical findings in patients with TTC19 mutations.
| F | M | F | M | M | M | M | F | M | F | F | M | F | M | M | M | F | M | M | |
| 5 years | 10 years | 5 years | 43 years | 27 years | 12 years | 15 years | 34 years | 1 year | 31 years | 18 months | 25 years | 8 years | Neonatal | 19 months | 3 years | 6 years | 3.5 years | 7 years | |
| Italian | Italian | Italian | Italian | Portuguese | Portuguese | Portuguese | Portuguese | Hispanic | Japanese | Arab | Japanese | Iraqi | Turkish | Austrian | Romanian | Romanian | Kuwaiti | Iranian | |
| Learning disability | Learning disability and gait ataxia | Regression of language and gait ataxia | Weakness of all extremities | Mood disorder and gait ataxia | Compulsive | Aggressive behavior | Aggressive behavior | Developmental delay and language regression | Dysarthria | Unsteady gait with frequent | Mood disorder and gait ataxia | Developmental delay | Lactic acidosis | Global developmental delay, ataxia, dysarthria, hypotonia | Developmental delay, ataxia, regression, hypotonia | Mild developmental delay, hypotonia | Recurrent stroke-like episodes, developmental delay | Aggressive behavior and hyperactivity | |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | +/NA | –/NA | –/– | –/– | +/NA | +/NA | –/– | NA | NA | +/NA | |
| Cognitive impairment | NA | + | NA | NA | + | + | + | + | NA | + | + | + | + | + | NA | NA | NA | + | + |
| Behavioral disorder | NA | NA | NA | NA | + | + | + | + | NA | NA | + | + | + | NA | NA | NA | – | NA | + |
| Ataxia | + | + | + | + | + | + | + | + | NA | + | + | + | + | + | + | + | – | + | + |
| Dysphagia | + | + | NA | NA | + | + | + | + | NA | NA | NA | NA | + | + | + | + | – | + | + |
| Dysarthria | + | + | + | + | + | + | + | + | NA | + | + | + | – | + | + | + | – | + | + |
| Spasticity | NA | NA | NA | + | + | + | + | NA | NA | NA | NA | + | – | + | + | + | – | NA | + |
| Epilepsy | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | – | + | + | + | – | NA | – |
| Hyperactive deep tendon reflexes | + | NA | NA | NA | + | + | + | + | NA | + | – | + | – | + | + | + | + | NA | + |
| Leukoencephalopathy, hyper-intense caudate nucleus, and cerebellar atrophy | NA | Cerebellar atrophy | NA | Olivo-ponto-cerebellar atrophy and hypersignal changes in caudate, putamen, cerebellar dentate nucleus, medial midbrain, and medullary olives on T2-weighted sequences | Progressing T2 high signal lesions in putamen, caudate body, and brainstem | Cerebellar atrophy and bilateral T2 high intensity at inferior olives | Mild cerebellar vermis atrophy and bilateral symmetrical T2 high intensity lesions in lentiform nucleus with cavitated aspects on FLAIR sequence | Cerebellar atrophy and symmetric T2 high intensity lesions in the inferior olives and adjacent to periaqueductal gray matter | Mild cerebellar and cerebral volume loss, bilateral patchy high signal T2/FLAIR, and hypo- to iso-intense T1 foci within the lentiform nuclei | Symmetrical T2-weighted hyper-intensities of basal ganglia and periventricular white matter | Bilateral T2-weighted hyper-intensities of the putamen, the caudate nucleus, and the mesencephalon periaqueductal gray matter | Hyper-intensities of nucleus lenticularis and nucleus caudatus, loss of volume in the putamen, and cerebral atrophy | Hyper-intensities in caput caudate nucleus and basal parts of the putamen, increased interfoliar spaces in cerebellum | Bilateral symmetrical T2-weighted hyper-intensities and cystic changes of putamina and the caudate nuclei | Bilateral hypersignal changes in caudate bodies and lentiform nuclei on T2 and FLAIR, cerebellar atrophy | ||||
Figure 1Brain MRI. (A) Axial FLAIR image of the patient showing hyper-signal changes bilaterally in caudate bodies and lentiform nuclei. (B) Coronal T2 image showing cerebellar atrophy.
Figure 2Schematic representation of TTC19 gene (GenBank accession no. NM_017775.3). The blue boxes indicate exons. Novel (shown in red) and previously reported mutations are shown.
Figure 3Sequence chromatograms of (A,B) parents and (C) the patient. The arrow indicates the site of the causative mutation.